167. Marfan syndrome Clinical trials / Disease details
Clinical trials : 21 / Drugs : 40 - (DrugBank : 11) / Drug target genes : 10 - Drug target pathways : 50
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01715207 (ClinicalTrials.gov) | June 2010 | 24/10/2012 | Comparison of Aliskiren vs Negative Controls on Aortic Stiffness in Patients With MFS | Comparison Study of the Effect of Aliskiren Versus Negative Controls on Aortic Stiffness in Patients With Marfan Syndrome Under Treatment With Atenolol | Marfan Syndrome | Drug: Aliskiren;Drug: Atenolol | Samsung Medical Center | NULL | Completed | 14 Years | 55 Years | All | 30 | Phase 3 | Korea, Republic of |
| 2 | NCT01145612 (ClinicalTrials.gov) | October 2008 | 15/6/2010 | Atenolol Versus Losartan in the Prevention of Progressive Dilation of the Aorta in Marfan Syndrome | A Clinical Trial to Assess the Efficacy and Safety of Losartan Versus Atenolol in the Prevention of Progressive Dilation of the Aorta in Patients With Marfan Syndrome. | Marfan Syndrome | Drug: Losartan;Drug: Atenolol | Forteza, Albert, M.D. | Ministry of Health, Spain | Active, not recruiting | 5 Years | 60 Years | Both | 140 | Phase 3 | Spain |
| 3 | EUCTR2007-001125-97-ES (EUCTR) | 20/05/2008 | 03/12/2007 | Eficacia y Seguridad de Losartán vs Atenolol en la prevención de la dilatación progresiva de la aorta en la población de pacientes con Síndrome de Marfan (Losartan vs atenolol efficacy and security in aortic dilatation prevention in Marfan syndrome) | Eficacia y Seguridad de Losartán vs Atenolol en la prevención de la dilatación progresiva de la aorta en la población de pacientes con Síndrome de Marfan (Losartan vs atenolol efficacy and security in aortic dilatation prevention in Marfan syndrome) | The aortic dilatation in Marfan syndrome with two different treatments: losartan vs atenolol MedDRA version: 9.1;Level: LLT;Classification code 10026829;Term: Marfan's syndrome | Trade Name: cozaar 50 INN or Proposed INN: LOSARTAN POTASSIUM Trade Name: blokium 50 INN or Proposed INN: ATENOLOL Trade Name: COZAAR INICIO 12,5 mg comprimidos recubiertos con pelicula INN or Proposed INN: LOSARTAN POTASSIUM Trade Name: BLOKIUM 50 mg comprimidos INN or Proposed INN: ATENOLOL | alberto forteza | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Spain | ||||
| 4 | NCT00593710 (ClinicalTrials.gov) | January 2008 | 3/1/2008 | Losartan Versus Atenolol for the Treatment of Marfan Syndrome | A Randomized Double-blind Study Assessing the Effects of Losartan Versus Atenolol on Pulse Wave Velocity and the Biophysical Properties of the Aorta in Patients With Marfan Syndrome | Marfan Syndrome | Drug: Losartan;Drug: Atenolol | University of British Columbia | Heart and Stroke Foundation of Canada | Completed | 12 Years | 25 Years | Both | 17 | Phase 2 | Canada |
| 5 | NCT00723801 (ClinicalTrials.gov) | October 2007 | 25/7/2008 | Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome | Effects of Losartan vs Atenolol on Aortic Stiffness and Diastolic Function in Adults With Marfan Syndrome | Marfan Syndrome | Drug: Atenolol;Drug: Losartan | Brigham and Women's Hospital | Boston Children’s Hospital | Completed | 25 Years | N/A | All | 40 | Phase 3 | United States |
| 6 | NCT00651235 (ClinicalTrials.gov) | February 2007 | 3/3/2008 | A Randomized, Open-label, LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome | A Randomized, Open-label, Active Control Trial to Evaluate the Effect of LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome | Marfan Syndrome | Drug: Losartan and Atenolol or Propranolol;Drug: Atenolol or Propranolol | National Taiwan University Hospital | NULL | Recruiting | 1 Year | N/A | Both | 44 | Phase 2 | Taiwan |
| 7 | NCT00429364 (ClinicalTrials.gov) | January 2007 | 29/1/2007 | Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome--Pediatric Heart Network | Trial of Beta Blocker Therapy (Atenolol) Versus Angiotensin II Receptor Blocker Therapy (Losartan) in Individuals With Marfan Syndrome (A Trial Conducted by the Pediatric Heart Network) | Marfan Syndrome | Drug: Losartan Potassium;Drug: Atenolol | New England Research Institutes | National Heart, Lung, and Blood Institute (NHLBI);FDA Office of Orphan Products Development;National Marfan Foundation | Completed | 6 Months | 25 Years | All | 608 | Phase 3 | United States;Belgium;Canada |
| 8 | EUCTR2006-003991-37-BE (EUCTR) | 13/12/2006 | 06/12/2006 | Trial of beta blocker therapy (atenolol) vs. angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome - Marfan Trial | Trial of beta blocker therapy (atenolol) vs. angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome - Marfan Trial | Marfan syndrome MedDRA version: 8.1;Level: LLT;Classification code 10026829;Term: Marfan's syndrome | Product Name: losartan INN or Proposed INN: Losartan potassium Product Name: losartan INN or Proposed INN: Losartan potassium Product Name: losartan INN or Proposed INN: Losartan potassium Product Name: Atenolol INN or Proposed INN: Atenolol Product Name: Atenolol INN or Proposed INN: Atenolol Product Name: Atenolol INN or Proposed INN: Atenolol | University Hospital Gent | NULL | Not Recruiting | Female: yes Male: yes | 600 | Belgium | |||
| 9 | NCT01295047 (ClinicalTrials.gov) | July 2006 | 11/2/2011 | Comparison of Medical Therapies in Marfan Syndrome. | Effects of Atenolol, Perindopril and Verapamil on Haemodynamic and Vascular Function in Marfan Syndrome - A Randomised Double-Blind Crossover Trial | Marfan Syndrome | Drug: Atenolol;Drug: VERAPAMIL;Drug: Perindopril | Cardiff University | NULL | Completed | 16 Years | 60 Years | Both | 18 | Phase 4 | United Kingdom |
| 10 | EUCTR2005-000749-13-GB (EUCTR) | 30/07/2005 | 20/06/2005 | A Randomised Double-Blind Trial of Medical Treatment In Marfan Syndrome. | A Randomised Double-Blind Trial of Medical Treatment In Marfan Syndrome. | Marfan Syndrome | Trade Name: Atenolol Product Name: Atenolol Product Code: N/A INN or Proposed INN: N/A Other descriptive name: N/A Trade Name: Coversyl Product Name: Coversyl Product Code: N/A INN or Proposed INN: N/A Other descriptive name: PERINDOPRIL Trade Name: Verapamil Product Name: Verapamil SR Product Code: N/A INN or Proposed INN: N/A Other descriptive name: N/A | Cardiff University | NULL | Not Recruiting | Female: yes Male: yes | 60 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes | United Kingdom |